These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21863510)

  • 1. [Multimodal therapy for colon cancer: state of the art].
    Weber T; Link KH
    Zentralbl Chir; 2011 Aug; 136(4):325-33. PubMed ID: 21863510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
    Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
    Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
    Prescrire Int; 2011 Feb; 20(113):46-9. PubMed ID: 21488594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A long-term survival case of liver and mediastinal LN metastases from colon cancer treated with intensive multimodal therapy].
    Nakahara O; Beppu T; Ishiko T; Mizumoto T; Masuda T; Hosaka S; Okabe H; Takamori H; Kanemitsu K; Hirota M; Baba H
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1792-4. PubMed ID: 17212109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer.
    Wein A; Riedel C; Brückl W; Kastl S; Reingruber B; Hohenberger W; Hahn EG
    Z Gastroenterol; 2001 Feb; 39(2):153-6. PubMed ID: 11253506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases.
    Prescrire Int; 2006 Jun; 15(83):109-1. PubMed ID: 16764102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rectal cancer: current status of multimodal therapy--when and how?].
    Gaedcke J; Liersch T; Hess C; Becker H; Rödel C; Ghadimi BM
    Zentralbl Chir; 2011 Aug; 136(4):334-42. PubMed ID: 21863511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease.
    Benson AB
    Clin Cancer Res; 2007 Nov; 13(22 Pt 2):6913s-20s. PubMed ID: 18006800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adjuvant therapy for colon cancer].
    Lordick F; Rosenberg R; Stein HJ; Peschel C; Siewert JR
    Dtsch Med Wochenschr; 2004 Oct; 129(44):2366-71. PubMed ID: 15497107
    [No Abstract]   [Full Text] [Related]  

  • 15. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.
    Karoui M; Rullier A; Luciani A; Bonnetain F; Auriault ML; Sarran A; Monges G; Trillaud H; Le Malicot K; Leroy K; Sobhani I; Bardier A; Moreau M; Brindel I; Seitz JF; Taieb J
    BMC Cancer; 2015 Jul; 15():511. PubMed ID: 26156156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Colon cancer: what is new in 2004?].
    André T; Louvet C; de Gramont A
    Bull Cancer; 2004 Jan; 91(1):75-80. PubMed ID: 14975808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of resected rectal cancer with hepatic node and multiple liver metastases effectively treated by preoperative modified FOLFOX6 and sLV5FU2 chemotherapy].
    Seshimo K; Oishi M; Toshima T; Ikeda H; Kato H; Yamamura M; Kodera M; Yamashita Y; Tanaka N; Fujita H; Shibagaki K; Taniguchi H; Matsuki T; Kobayashi K; Takita K
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):477-80. PubMed ID: 22421784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.
    Karoui M; Gallois C; Piessen G; Legoux JL; Barbier E; De Chaisemartin C; Lecaille C; Bouche O; Ammarguellat H; Brunetti F; Prudhomme M; Regimbeau JM; Glehen O; Lievre A; Portier G; Hartwig J; Goujon G; Romain B; Lepage C; Taieb J;
    Colorectal Dis; 2021 Jun; 23(6):1357-1369. PubMed ID: 33580623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.